Síndrome Respiratória Aguda: uma resposta imunológica exacerbada ao COVID19 / Acute Respiratory Syndrome: an exacerbated immune response to COVID19

Authors

  • David Balbino Pascoal
  • Ana Clara Silva Carvalho
  • Lucas Emanuel Lemos Fontes Silva Mata
  • Tadeu Peixoto Lopes
  • Lorenna Peixoto Lopes
  • Cristiane Monteiro da Cruz

DOI:

https://doi.org/10.34119/bjhrv3n2-138

Keywords:

síndrome respiratória agua, sistema imune, SARS-CoV-2, coronavírus.

Abstract

Os coronavírus pertencem a família de vírus causadores de infecções respiratórias em seres humanos e animais. O coronavírus SARS-CoV-2 é responsável pelo desenvolvimento da síndrome respiratória aguda caracterizada por febre, tosse seca, dor de cabeça, dores musculares e dificuldade em respirar. Estes sintomas são característicos da ativação do sistema imune em resposta ao processo infeccioso iniciado pelo vírus. O receptor do SARS-CoV-2 é a enzima conversora de angiotensina 2 (ACE2), expressa, principalmente, nas células epiteliais alveolares AT2 pulmonares, que são particularmente propensas a infecções virais. O rompimento da barreira inespecífica induz a liberação de citocinas responsáveis pelo início da resposta imune. A transmissão do SARS-CoV-2 ocorre através de gotículas respiratórias e do contato direto com as membranas mucosas e os sintomas incluem febre, fadiga e tosse seca, entre outros. Atualmente, a principal forma de diagnóstico inclui uma abordagem clínica e um exame de reação em cadeia da polimerase em tempo real (RT-PCR) para detecção do ácido nucleico do vírus no paciente possivelmente infectado, porém, esse teste ainda apresenta muitas limitações, tornando-se inadequado para uma triagem rápida e simples dos pacientes. O desenvolvimento de testes sorológicos de curto prazo para diagnóstico baseados na identificação de proteínas específicas durante a infecção viral viabilizará a triagem rápida e manejo dos pacientes infectados. O objetivo deste estudo é associar a resposta imunológica ao desenvolvimento da infecção pelo SAR-CoV-2.

 

References

Kenneth McIntosh, MD. Novel Coronavirus (2019-nCov). UpToDate Jan 2020 uptodate.com/contents/coronavirus-disease-2019-covid-19). Acess 27/03/2020

N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 382 (2020), pp. 727-733, 10.1056/NEJMoa2001017.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomiccharacterisationandepidemiologyof 2019 novel coronavirus: implications for virusoriginsand receptor binding. Lancet. 2020;395(10224):565. Epub 2020 Jan 30.

Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, et al. SARS-CoV-2 viral load in upperrespiratorysamplesfrominfectedpatients. J. N Engl J Med. 2020;

Amrane S, Dupont HT, Doudier B, Eldin, C, Hocquart M,Mailhe M, et al. Rapid viral diagnosisandambulatory management ofsuspected COVID-19 cases presenting atthe infectiousdiseasesreferral hospital in Marseille, France, - January 31st toMarch 1st, 2020: A respiratoryvirus snapshot. Marseille:https://www.ncbi.nlm.nih.gov/pubmed/32205269.

Russel, Clark D; Millar, Jonathan E; Baillie, J Kenneth. Clinicalevidence does notsupportcorticosteroidtreatment for 2019-nCov lunginjury. The lancet .February 15, 2020.V395, ISSUE 10223, P473-475.

Y. Zhao, Z. Zhao, Y. Wang, Y. Zhou, Y. Ma, W. Zuo. Single-cell RNA expressionprofilingof ACE2, theputative receptor of Wuhan 2019-nCov Biorxiv, 2020 [Internet]. V(1) (2020) [Internet]. p. 26.919985, 10.1101/2020.01.26.919985

Kristian G. Andersen, Andrew Rambaut, W. Ian Lipkin,Edward C. Holmes&Robert F. Garry. The proximal originof SARS-CoV-2.Nature Medicine (2020) [Internet].Published: 17 March 2020

Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Corona vírus Disease 2019 in China. N Engl J Med [Internet]. 2020;1–13. Availablefrom: http://www.ncbi.nlm.nih.gov/pubmed/32109013

Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmissionof 2019-NCOV infectionfromanasymptomaticcontact in Germany. N Engl J Med [Internet]. 2020;382(10):970–1.

Peiris JSM, Chu CM, Cheng VCC, et al. Clinicalprogressionand viral load in a communityoutbreakofcoronavirus-associated SARS pneumonia: a prospectivestudy. Lancet 2003 [Internet]. 361: 1767 - 1772

Tsang TK, Cowling BJ, Fang VJ, et al.Influenza A VirusSheddingandInfectivity in Households. J InfectDis 2015 [Internet]; 212: 1420 - 1428.

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognitionby novel coronavirusfrom Wuhan: Ananalysisbasedondecade-longstructuralstudiesof SARS. J Virol. 2020. DOI: 10.1128/JVI.00127-20.

M. Hoffmann, H. Kleine Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, et al. SARS-CoV-2 cellentrydependson ACE2 and TMPRSS2 andisblockedby a clinicallyproven protease inhibitor. Cell (2020) [Internet]. S0092-8674 (20) 30229-4. doi: 10.1016 / j.cell.2020.02.052.

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirusinfectionsandimmune responses.Journalof medical virology [Internet]. Wiley Online Library, 2020.

Akira S, Uematsu S, Takeuchi O. Pathogenrecognitionandinnateimmunity. Cell. 2006 [Internet].124(4):783?801.

Kawai T, Akira S. The role ofpattern?recognitionreceptors in innateimmunity: updateonToll?likereceptors. NatureImmunol. 2010;11(5):373?384.

Hamada H, Bassity E, Moscas A, et al. Multipleredundanteffectormechanismsof CD8+ T cellsprotectagainst influenza infection. [J] .JImmunol, 2013.

Zhou YG, Fu BQ, Zheng XH, et al. Aberrantpathogenic GM-CSF+ T cellsandinflammatory CD14+CD16+ monocytes in severepulmonarysyndromepatientsof a new coronavirus. [J / OL]. Biorxiv, 2020.

Braciale TJ, Sun J, Kim TS. Regulatingtheadaptiveimmune response torespiratoryvirusinfection. [J] Nat RevImmunol, 2012.

Waffarn EE, Baumgarth N. Protective B cell responses toflu - no flu!. [J] .JImmunol, 2011.

Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Inductionofpro-inflammatorycytokines (IL-1 and IL-6) andlunginflammationby Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatorystrategies. J BiolRegulHomeostAgents. 2020.

He JH, Tao HY, Yan YM, et al. Molecular mechanismo fevolutionandhumaninfectionwiththe new coronavirus (2019-nCoV) [J / OL] .Biorxiv, 2020.

Cecere TE, Todd SM, Leroith T. Regulatory T cells in arterivirusandcoronavirusinfections: do theyprotectagainstdiseaseorenhance it? Viruses. 2012 [Internet];4(5):833?846.

Wan SX, Yi QJ, Fan SB, et al. Características de subconjuntos de linfócitos e citocinas no sangue periférico de 123 pacientes hospitalizados com 2019 nova pneumonia por coronavírus (NCP) [J / OL] .medRxiv, 2020.

Iwasaki A, Medzhitov R. Regulationofadaptiveimmunitybytheinnateimmune system [J.] Science, 2010.

Yoshikawa T, Hill T, Li K, Peters CJ, Tseng C-TK. SevereAcuteRespiratorySyndrome (SARS) Coronavirus-InducedLungEpithelialCytokinesExacerbate SARS PathogenesisbyModulatingIntrinsicFunctionsofMonocyteDerivedMacrophagesandDendriticCells. J Virol. 2009;83(7):3039–48.

Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, FrydasI,et al. J BiolRegulHomeostAgents. 2020.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinicalfeaturesofpatientsinfectedwith 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. ClinicalCharacteristicsof 138 HospitalizedPatientswith 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J AmMedAssoc [internet]. 2020;1–9.

Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associatedwiththe 2019 novel coronavirusindicatingperson-to-persontransmission: a studyof a family cluster. Lancet. 2020;395(10223):514. Epub 2020 Jan 24.

Liang T. Handbookof COVID-19 PreventionandTreatment. Hangzhou: Jack Ma Foundation; 2020. Disponível emhttps://covid-19.alibabacloud.com/.

Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. ProfilingEarly Humoral Response to Diagnose Novel CoronavirusDisease (COVID-19). ClinInfectDis. 2020;

Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibitsbothepidemicandzoonoticcoronaviruses. SciTransl Med. 2017;9(396)

Hanff, Thomas C; Harhay, Michael O; Brown, Tyler S; Cohen, Jordana B; Mohareb, Amir M. IsThereanAssociationBetween COVID-19 MortalityandtheRenin-Angiotensin System—a Call for EpidemiologicInvestigations. ClinicalInfectiousDiseases, ciaa329, https://doi.org/10.1093/cid/ciaa329

Patel AB andVermaA . COVID-19 andAngiotensin-ConvertingEnzymeInhibitorsandAngiotensin Receptor Blockers. JAMA. 2020;

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 andthe cardiovascular system. Nat RevCardiol. 2020;

EuropeanSocietyofHypertension. ESH Statementon COVID-19. https://www.eshonline.org/spotlights/esh-statement-on-covid-19/ (AccessedonMarch 18, 2020).

Liu J, CaoR ,Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a lesstoxicderivativeofchloroquine, iseffective in inhibiting SARS-CoV-2 infection in vitro. Liu et al. Cell Discovery (2020) 6:16 Cell Discovery https://doi.org/10.1038/s41421-020-0.

Gautret et al. (2020) Hydroxychloroquineandazithromycin as a treatmentof COVID?19: resultsofan open?label non?randomizedclinicaltrial. International Journal of AntimicrobialAgents – In Press 17 March 2020 DOI:10.1016/j.ijantimicag.2020.105949.

CDC. Therapeuticoptions for patientswith COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html (AccessedonMarch 22, 2020).

Reuters. China approves use of Roche drug in battleagainstcoronaviruscomplications. https://www.reuters.com/article/us-health-coronavirus-china-roche-hldg/china-approves-use-of-roche-arthritis-drug-for-coronavirus-patients-idUSKBN20R0LF (AccessedonMarch 11, 2020).

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. ClinicalCharacteristicsofCoronavirusDisease 2019 in China. N Engl J Med. 2020;

Statementfromthe American Heart Association, the Heart FailureSocietyofAmericaandthe American CollegeofCardiology. PatientstakingACE-iandARBswhocontract COVID-19 should continue treatment, unlessotherwiseadvisedbytheirphysician. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician (AccessedonMarch 18, 2020).

Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. DevelopmentandClinicalApplicationof A RapidIgM-IgGCombinedAntibody Test for SARS-CoV-2 InfectionDiagnosis. 2020.

Published

2020-04-07

How to Cite

PASCOAL, D. B.; CARVALHO, A. C. S.; MATA, L. E. L. F. S.; LOPES, T. P.; LOPES, L. P.; CRUZ, C. M. da. Síndrome Respiratória Aguda: uma resposta imunológica exacerbada ao COVID19 / Acute Respiratory Syndrome: an exacerbated immune response to COVID19. Brazilian Journal of Health Review, [S. l.], v. 3, n. 2, p. 2978–2994, 2020. DOI: 10.34119/bjhrv3n2-138. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/8568. Acesso em: 28 mar. 2024.

Issue

Section

Original Papers